Related Experiment Videos
[Tumor markers in lymphoproliferative disorders]
1Department of Medicine, National Cancer Center Hospital East.
The tumor markers detected in patients' peripheral blood with lymphoproliferative disorders, especially malignant lymphomas were reviewed and classified as follows: I) Biochemical marker and reactive protein, II) Cytokine and soluble cytokine receptor, III) Soluble form of tumor-surface marker, IV) Circulating tumor and V) Others. They were reported to be useful to predict the prognosis, to monitor the effects of the treatment, to detect minimum residual disease and to diagnose early relapse. At present clinical practice, non-specific tumor markers such as LDH, ESR, CRP and beta 2-MG are generally used. In the future when the convenient methods of biological assays including molecular biology-technique are developed, it will be possible to detect the specific tumor markers in clinical setting.
The tumor markers detected in patients' peripheral blood with lymphoproliferative disorders, especially malignant lymphomas were reviewed and classified as follows: I) Biochemical marker and reactive protein, II) Cytokine and soluble cytokine receptor, III) Soluble form of tumor-surface marker, IV) Circulating tumor and V) Others. They were reported to be useful to predict the prognosis, to monitor the effects of the treatment, to detect minimum residual disease and to diagnose early relapse. At present clinical practice, non-specific tumor markers such as LDH, ESR, CRP and beta 2-MG are generally used. In the future when the convenient methods of biological assays including molecular biology-technique are developed, it will be possible to detect the specific tumor markers in clinical setting.